Skip to main
MDWD
MDWD logo

MediWound (MDWD) Stock Forecast & Price Target

MediWound (MDWD) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MediWound Ltd is positioned favorably due to its innovative biopharmaceutical products, including the FDA-approved NexoBrid, which addresses significant unmet medical needs in the treatment of severe burns and chronic wounds. The company's revenue stream is primarily generated from the United States, with additional contributions from the European Union and other international markets, highlighting its potential for growth in diverse regions. Although the recent financial results for 1Q24 showed total revenues of $4.0 million, slightly below consensus estimates, MediWound's ongoing developments and product pipeline remain key indicators of long-term financial viability and growth potential.

Bears say

MediWound Ltd has postponed the U.S. launch of its product EscharEx by one year, now scheduled for the third quarter of 2028, which indicates potential delays in revenue generation and market penetration. The continuous indication of no income or loss from discontinued operations suggests a lack of significant financial activities that could bolster earnings or offset losses. Such factors contribute to a negative outlook on the company's stock, reflecting concerns regarding growth timelines and overall financial performance.

MediWound (MDWD) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MediWound and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MediWound (MDWD) Forecast

Analysts have given MediWound (MDWD) a Strong Buy based on their latest research and market trends.

According to 2 analysts, MediWound (MDWD) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MediWound (MDWD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.